AQP4 and Alzheimer disease: Despite there being no single drug that has been approved to successfully target AQP4 [77], new studies suggest that modulators of sleep or AQP4 (by targeting the trafficking mechanism or membrane abundance rather than pore-blocking) could be novel targets for early intervention in AD and other protein-misfolding diseases [78,79].